Cargando…
Specialty molecules from plants and in vitro cultures as new drugs: regulatory considerations from flask to patient
Few therapeutic specialty molecules from in vitro cultures beyond paclitaxel have come to market and although other more complex products like ginseng have also appeared, success has been limited. Often it is not the science that is limiting, but rather regulatory issues that limit considerations of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942155/ https://www.ncbi.nlm.nih.gov/pubmed/35345535 http://dx.doi.org/10.1007/s11240-022-02287-4 |